~~<i id='9498D8D496'><strike id='9498D8D496'><tt id='9498D8D496'><pre id='9498D8D496'></pre></tt></strike></i>~~

Home» Wikipedia» comprehensive

comprehensive

author：hotspot 2025-09-28 15:12:05 Page View：13

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 'A game
Next article： Apple is now the first public company to be valued at $3 trillion

focus

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

Transgender sports debate: Physicians say bans are health issue

AnjumNaveed/APAlmosthalfofU.S.stateshavebannedorrestrictedtransyouths’accesstogender-affirmingpubert

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

FDA weighs limits of animal data in assessing artificial wombs

APStockTheFoodandDrugAdministration’sadvisorypanelofpediatricexpertsmetonTuesdaytodiscussadvancesina

WSS

comprehensive

comprehensive

leisure time

focus

FDA weighs limits of animal data in assessing artificial wombs